Introduction {#s1}
============

Colorectal cancer (CRC) incidence in China has been increasing over the past decades ([@B1]--[@B3]). CRC ranks fifth in the causes of cancer morbidity and mortality ([@B4], [@B5]). 5-Flurouracil (5-FU)-based adjuvant chemotherapy is the standard treatment for locally advanced CRC patients. However, up to 40% of advanced CRC patients cannot benefit from adjuvant chemotherapy and will eventually relapse ([@B6]).

Great effort has been made to identify markers to predict the benefit from adjuvant chemotherapy. However, the only biomarker at present in clinical use is carcinoembryonic antigen (CEA), which is widely used to monitor treatment response and to detect recurrence ([@B7]). A specimen-derived biomarker from surgery is urgently required to determine the following adjuvant treatment. Presently the treatment is mainly based on the tumor/node/metastasis (TNM) stage. Therefore, it is quite crucial to identify and validate markers from surgical pathologic samples, which enables identification of patients at high and low risk of early relapse and progression, independently of the tumor stage. Thus, the biomarkers have great implication in individualized adjuvant treatment and follow-up. The primary aim of the present study was to evaluate the tumor expression of estrogen receptor 1 (ESR1) from CRC patients in this context.

ESR1, a nuclear receptor subfamily 3, group A, member 1, is one of two main types of estrogen receptor (ER), which is activated by the sex hormone estrogen. Although ESR1 expression levels remain low in both normal and cancerous colonocytes, our recent study revealed that ESR1 expression attributed to inferior clinical outcome in CRC patients ([@B8]). Moreover, other studies indicated that ESR1 may be implicated in the development and progression of CRCs ([@B9]--[@B11]). However, whether ESR1 expression can predict the efficacy of adjuvant chemotherapy to influence survival and how it regulates chemosensitivity remain unclear. The primary objective of this study was therefore to explore the correlation between ESR1 expression and adjuvant chemotherapy outcome in training and validation cohorts of locally advanced CRC patients.

Materials and Methods {#s2}
=====================

Clinical Specimens
------------------

We retrospectively collected 467 paraffin-embedded resection samples from patients from November 2007 until October 2010. Those eligible for inclusion were patients who underwent curative resection for stage II--III CRC at Sun Yat-Sen University Cancer Center (South China). All biological experiments were conducted under the "Laboratory Safety Rules of Guangdong Institute of Gastroenterology" thus, standard biosecurity and institutional safety procedures have been adhered to Standardized Operation. Patients receiving neoadjuvant treatment were excluded. Clinical characteristics including age, gender, tumor localization, tumor stage, adjuvant chemotherapy, chemotherapy regimen, and survival were obtained from patient files and registries.

Treatment
---------

The treatment strategy was determined by clinical stage, the multidisciplinary team\'s (MDT) decision, and patient choice. All patients from training cohort received definitive-intent surgery. Patients have not received adjuvant chemotherapy mainly due to patients\' refusal. 5-FU-based chemotherapy was delivered. Adjuvant chemotherapy consisted of oxaliplatin (130 mg/m^2^, day 1) with capecitabine (1,000 mg/m^2^, bid, days 1--14) or 5-FU (bolus 400 mg/m^2^ and then 1,200 mg/m^2^/day over 46--48 h) every 3 weeks or Leucovorin (400 or 200 mg/m^2^, day 1), with 5-FU (bolus 400 mg/m^2^ and then 1,200 mg/m^2^/day over 46--48 h) every 2 weeks.

Immunohistochemistry
--------------------

Firstly, the fresh tissues were fixed in 10% buffered formalin (PH 7.0) and embedded in paraffin. The paraffin-embedded tumor samples were then sectioned continuously into 4-μm-thick sections. Then the sections were dewaxed in xylene and rehydrated in graded alcohols. A normal rabbit IgG antibody was used as a negative control. Following antigen retrieval by microwave heating (95°C for 20 min), sections were then incubated with ESR1 (Clone SP1, Ventana Medical Systems. Inc.) at 4°C overnight. After washing, a horseradish peroxidase-labeled goat antibody against a mouse/rabbit secondary antibody (Envision; Dako, Glostrup, Denmark) was added, followed by incubation at room temperature for 30 min. The signal was then detected with 3,3′-diaminobenzidine tetrahydrochloride (DAB). Two independent pathologists blinded to the clinical information scored the ESR1 expression levels in tumor cells by assessing (a) the proportion of positively stained cells (0, \< 5%; 1, 6--25%; 2, 26--50%; 3, 51--75%; 4, \>75%) and (b) the signal intensity (0, no signal; 1, weak; 2, moderate; 3, strong). The score was the product of a × b. Considering that the number of patients with score \> 0 in ESR1 was very low, we used dichotomic classification (positive/negative). Therefore, a positive group (a × b\>0) and a negative group (a × b = 0) were used ([Figure S1](#SM1){ref-type="supplementary-material"}).

Gene Expression Analyses
------------------------

Two public data sets were analyzed in the validation stage, CRC mRNA microarray data [GSE39582](GSE39582) and [GSE14333](GSE14333) from Gene Expression Omnibus (GEO). Preprocessed data from GEO were downloaded using the Bioconductor package "GEO query." The prognosis performance of ESR1 was assessed with Kaplan--Meier survival analysis.

Cell Growth Inhibition Assay
----------------------------

HCT116, KM12, DLD1, and SW480 cell lines were the cell lines that we used in our study. These cell lines are widely recognized CRC cell lines for research. And more importantly, we have selected two cell lines (DLD1, SW480) with high ESR1 expression and another two cell lines (HCT116, KM12) with low ESR1 expression for further research. The cells were resuspended in the medium as single-cell suspension and seeded in a 96-well plate at a density of 5 × 103 cells/well. After culture overnight, 5-FU was serially diluted with a culture medium and added in a 96-well plate. After incubation for 48 h, 20 μl of MTS reagent (G358A, Promega) was pipetted into each well of the 96-well plate and incubated for 4 h in a 37°C incubator. The absorbance was determined by a microplate analyzer OD490 at 490 nm. Cell survival rate = (OD490 experimental hole -OD490 blank hole)/(OD490 control hole -OD490 blank hole) 100%. Experiments were performed in triplicate and the average value was taken.

Protein Extraction and Western Blotting
---------------------------------------

Total proteins were lysed by incubating with RIPA buffer (Beyotime, China) that was supplemented with a protease inhibitor cocktail (Sigma, China). The protein concentrations were measured using a BCA Protein Assay Kit (Boster, China). Proteins were separated by SDS-PAGE using a 10% polyacrylamide gel and transferred to nitrocellulose membranes (BioRad). After blocking by 5% milk for 1 h at room temperature, the membranes were incubated with a relative antibody at 4°C overnight. Membranes were incubated with HRP-conjugated goat anti-mouse antibody (1:10,000) for 1 h. The signal strength of revealed protein bands was detected with an enhanced chemiluminescence (ECL) substrate and captured with Image-Lab software (BioRad). Detection of the relative protein band intensities of GAPDH served as an internal loading control.

The Establishment of Stable Knockdown and Overexpressed Cells
-------------------------------------------------------------

The open-reading frame of ESR1 was amplified from the cDNA of 293T cells and inserted into the Psin vector. CRC cells were stably transduced with ESR1 overexpressing lentiviral and Psin control vectors. For the ESR1 knockdown cells, CRC cells were transfected with PLKO vectors and transduced with ESR1 knockdown lentiviral vectors (ESR1 sh01: GGAGAATGTTGAAACACAA, sh02: CCAGTGCACCATTGATAAA). Three Lentiviral Packaging Plasmid (psPAX2: pMD2.G = 6: 3: 1.5 μg) were used to transfecting into 293T cells. The released virus was harvested and concentrated by ultracentrifugation. To establish the stable knockdown and overexpressing cells, all cells were transduced with the lentivirus at a multiplicity of infection (MOI) of 10 with 5 μg/ml polybrene (Sigma). The stable expressing cells were selected by treating with puromycin for 2 weeks.

Statistical Analysis
--------------------

Statistical analyses were performed in SPSS version 19 (IBM, Corporation, Armonk, NY, USA) and R 3.2.4. Software (<http://www.r-project.org>). Patient characteristics were compared by *t*-test and the χ^2^ test of independence. Overall survival was estimated by the Kaplan--Meier method, and the survival curves were compared by log-rank tests. The optimal cutoff value of the ESR1 expression level was determined using the X-tile (Yale University, New Haven, CT, USA) software ([@B12]). OS was measured from commencement of treatment to death or the date of last follow-up visit for surviving patients. The median follow-up duration was 46.7 months for training. The main causes of death were relapse of tumor and cardiovascular and cerebrovascular diseases.

Cox proportional hazards models were used for multivariate analyses to calculate the hazard ratios (HRs) and to test independent significance. A test for an interaction between adjuvant chemotherapy and ESR1 expression was pre-specified. The training set has developed a model for survival, whose variables were then applied in the validation set. The chosen variables were already well-established clinically relevant covariates such as demographic parameters (age, gender), disease stage, localization, and adjuvant treatment. The criterion for statistical significance was set at p = 0.05 on two-sided tests.

Results {#s3}
=======

ESR1 Expression Is Negatively Correlated With Better Overall Survival (OS) in Locally Advanced Patients Treated With Adjuvant Chemotherapy in the Training Set
--------------------------------------------------------------------------------------------------------------------------------------------------------------

To investigate the clinical relevance of ESR1 expression, the present study analyzed ESR1 expression in tumor tissue from 467 locally advanced CRC patients by IHC staining. Among these patients, 337 patients were treated with adjuvant chemotherapy. Seventy-two (32%) stage II patients and 58 (24%) stage III patients did not receive adjuvant chemotherapy. The rate of ESR1 expression was significantly higher in colon tumor tissue compared with that in rectum (*p* = 0.002). The correlation between ESR1 and tumor location from GSE39582 dataset was further validated ([Table 1](#T1){ref-type="table"}).

###### 

Correlation between expression of ESR1 and clinicopathological features in training and validation sets.

  **Factors**                                           **Training set**   ***p***   **Validation set**   ***p***         
  ----------------------------------------------------- ------------------ --------- -------------------- --------- ----- -------
                                                        73                 394                            48        412   
  **Age**                                                                            0.524                                1
      ≤ 60                                              36                 212                            13        109   
     \>60                                               37                 182                            35        303   
  **Sex**                                                                            1.000                                0.048
     Male                                               43                 233                            20        238   
     Female                                             30                 161                            28        174   
  **Tumor location[^\*^](#TN1){ref-type="table-fn"}**                                0.002                                0.01
     Colon/Proximal colon                               46                 170                            28        159   
     Rectum/Distal colon                                27                 224                            20        253   
  **Stage**                                                                          1.000                                1
     Stage II                                           35                 190                            27        232   
     Stage III                                          38                 204                            21        180   
  **Adjuvant chemotherapy**                                                          0.67                                 0.456
     Yes                                                51                 286                            24        178   
     No                                                 22                 108                            24        234   

*Baseline characteristics of the two cohorts regarding demography (age and gender), tumor features (stage and localization), and ESR1 expression and whether or not patients in stages II--III received adjuvant chemotherapy*.

*Tumor location for colon cancer patients from external validation cohort was proximal and distal colon*.

To further determine the effect of ESR1 expression on adjuvant chemotherapy in stage II and III CRC patients, the Cox regression model was employed to show strong interactions between ESR1 expression and adjuvant chemotherapy in the multivariate analyses, with *p* = 0.019 ([Table 2](#T2){ref-type="table"}).

###### 

Multivariate survival analyses including adjuvant chemotherapy on stage II--III CRC patients.

                                                                    **Hazard ratio (95% CI)**   ***P*-value**
  ----------------------------------------------------------------- --------------------------- ---------------
  **Number of patients**                                            467                         
  **Age**                                                                                       
     \>60 vs. ≤ 60 years                                            0.988 (0.676--1.445)        0.952
  **Gender**                                                                                    
     Female vs. male                                                0.975 (0.664--1.423)        0.896
  **Stage**                                                                                     
     Stage III vs. II                                               1.889 (1.270--2.808)        0.002
  **Localization**                                                                              
     Rectum vs. colon                                               1.374 (0.935--2.019)        0.106
  **ESR1[^\*^](#TN2){ref-type="table-fn"} adjuvant chemotherapy**   1.792 (1.100--2.921)        0.019

*Multivariate analyses for patients in stages II and III. The variables include age, gender, stage, localization, interaction between ESR1 expression, and adjuvant chemotherapy*.

*Refers to the interaction between ESR1 expression and adjuvant chemotherapy*.

In the additional subgroup analyses, significantly improved overall survival in patients receiving 5-FU-based adjuvant chemotherapy in the training set (*p* = 0.003) and the validation set (*p* \< 0.001) was found to be inversely associated with the expression of ESR1 ([Figure 1](#F1){ref-type="fig"}). On the contrary, such association in patients receiving no adjuvant chemotherapy was found to be not significant ([Figure 1](#F1){ref-type="fig"}). For patients without/low ESR1 expression, adjuvant chemotherapy improved overall survival in training (*p* = 0.024) and validation (*p* = 0.024) cohorts comparing with no adjuvant chemotherapy. For patients with ESR1 expression, no correlation between adjuvant chemotherapy and overall survival was found in the training cohort, while adjuvant chemotherapy decreased overall survival in the validation cohort for patients with high ESR1 expression ([Figure 2](#F2){ref-type="fig"}). Moreover, significant inverse association between ESR1 and disease-free survival was found in two independent public datasets (*p* = 0.035 and *p* = 0.006, respectively). Disease-free survival was not associated with ESR1 expression in no adjuvant chemotherapy subgroup ([Figure S2](#SM1){ref-type="supplementary-material"}).

![Correlation between the expression of ESR1 and overall survival. Kaplan--Meier survival curves of the overall survival in CRC patients with **(A)** or without **(B)** adjuvant chemotherapy in the training cohort and with **(C)** or without **(D)** adjuvant chemotherapy in the validation cohort. The log-rank analysis was used to test for significance.](fonc-10-00214-g0001){#F1}

![Correlation between adjuvant chemotherapy and overall survival. Kaplan--Meier survival curves of the overall survival in CRC patients with **(A)** or without **(B)** ESR1 expression in the training cohort and with high **(C)** or low **(D)** ESR1 expression in the validation cohort. The log-rank analysis was used to test for significance.](fonc-10-00214-g0002){#F2}

ESR1 Expression Is Negatively Associated With CRC Cell Sensitivity to 5-FU
--------------------------------------------------------------------------

To further investigate whether the ESR1 level was correlated with CRC cell chemosensitivity to 5-FU *in vitro*, four CRC cell lines were treated with different concentration of 5-FU for 72 h. ESR1-overexpressed cells were less sensitive to 5-FU than control, which led to higher cell viability ([Figures 3A,B](#F3){ref-type="fig"}). Knockdown of ESR1 expression in DLD1 and SW480 cells showed enhancement of cytotoxicity of 5-FU after 72 h of exposure ([Figures 3C,D](#F3){ref-type="fig"}). Thus, these results suggested that ESR1 expression was negatively correlated with CRC cell sensitivity to 5-FU. Western blot analysis indicated that ESR1 overexpressing in CRC cells displayed increased activation of P65 and ESR1 knocking down displayed decreased activation of P65 ([Figure 3E](#F3){ref-type="fig"}).

![ESR1 expression is negatively correlated with CRC cell sensitivity to 5-FU. ESR1 was up-regulated in **(A)** HCT116 and **(B)** KM12 cells, which were treated with increasing concentrations of 5-FU after transfection with ESR1 or control. Overexpression ESR1 decreases sensitivity to 5-FU. ESR1 was knocked down in **(C)** DLD1 cell and **(D)** sw480 cell, which were treated with increasing concentrations of 5-FU after transfection with ESR1 or control. Knocking down ESR1 gives rise to higher sensitivity to 5-FU. **(E)** KM12 and ESR1 overexpressing HCT116 and KM12 cells displayed increased activation of P65 and ESR1 knocking down DLD1 and sw480 cells displayed decreased activation of P65. \**p* \< 0.05, \*\**p* \< 0.01.](fonc-10-00214-g0003){#F3}

Discussion {#s4}
==========

To the best of our knowledge, this is the first study to investigate the potential predictive role of ESR1 expression in stage II--III CRC patients. This study shows that strong interactions between ESR1 expression and adjuvant chemotherapy existed in both the training set and the validation set. With the use of the validation cohort, this paper reaches evidence II level as defined by Simon et al. ([@B13]).

There is a great need for biomarkers from surgical specimen to identify patients with high risk of relapse and progression, thereby allowing for more intensive adjuvant treatment and stricter follow-up with the aim to improve the survival.

The prognostic significance of the biomarker was present in the subpopulation of locally advanced CRC patients receiving adjuvant chemotherapy in the training and validation sets. Patients with low ESR1 expression who accounts for the most majority of CRC patients benefitted from adjuvant chemotherapy in both cohorts. Additionally, our finding may suggest that ESR1 expression in tumor tissue after curative resection is a predictor of poor response to 5-FU-based adjuvant chemotherapy. This indicates that ESR1 may deregulate chemotherapy drugs\' sensitivity as it did in breast cancer ([@B14], [@B15]). The exact mechanism behind the drug resistance of ESR1 expression in CRC is largely unknown. The NF-κB pathway was a well-known pathway, which has been reported to be linked to various cellular processes in cancer including chemoresistance ([@B16]). P65 is the key protein of the NF-κB pathway, and its phosphorylation activates the NF-κB pathway. Our study indicated that activating phosphorylation of P65 by ESR1 may play a role in the 5-FU resistance, which gave a hint to investigate NF-κB signal pathways. In accordance with our study, NF-κB signal pathways were reported to contribute to chemotherapy resistance in many cancers ([@B17], [@B18]). Furthermore, a recent study also demonstrated that NF-κB played a role in irinotecan-resistant colon cancer cells ([@B19]). Therefore, further study to investigate the specific molecular mechanism behind the drug resistance of ESR1 expression is warranted. The significant interaction regarding adjuvant chemotherapy and ESR1 expression in these cohorts indicates that the current adjuvant chemotherapy may not be enough for patients with ESR1 expression. Hormone therapy (HT) remains one of the mainstay treatments for breast cancer patients expressing ESR1. Furthermore, several studies suggested that HT may play a crucial role in its protective effects on colon cancer ([@B20], [@B21]). Although the addition of HT to adjuvant chemotherapy may be a potential strategy for stage II and III patients with ESR1 expression, we would not advocate altering current treatment decisions according to our findings unless it was validated by further clinical trials. This special aspect of the applicability of the biomarker must be further assessed due to the lack of prospective evidence of clinical trials and the increased rates of cardiovascular events with HT ([@B22]).

A single biomarker is not possibly sufficient to describe the complex biological characteristics of the tumor and its microenvironment. Sargent et al. showed that patients with dMMR status cannot benefit from 5-FU adjuvant chemotherapy in stage II colon cancer ([@B23]), which indicated that MMR status was quite crucial. Although our study indicated the predictive value of ESR1 in stage II--III CRC, further prospective study that validates the predictive value of ESR1 according to the MMR status in CRC is demanded. A series of valid biomarkers of cancer ([@B24]) could prove useful for patient-tailored individualized treatments based on molecular features in addition to already established clinicopathological characteristics.

Although the potential biological reason why ESR1 expression affects the prognosis of stage II--III CRC patients receiving adjuvant chemotherapy remains to be specifically clarified, the results validated in the present study indicate the clinical implication of ESR1 expression in these subsets of CRC patients. When treating CRC patients, whether implementation of the ESR1 IHC staining to the clinical routine could offer an improved survival needs prospective studies to evaluate. Interpreting the possibility of the addition of HT to adjuvant chemotherapy in patients with ESR1 expression, this strategy needs to be validated beforehand in CRC cell lines, animal models, and then clinical trials.

Conclusion {#s5}
==========

The results of the current study indicated independent predictive influence of tumor cell expression of ESR1 on 5-FU-based adjuvant chemotherapy from stage II--III CRC patients. Additionally, activating phosphorylation of P65 by ESR1 may play a role in the 5-FU resistance. Further sufficiently powered, prospective studies must be performed with concentration on conforming the predictive value.
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